TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 665.00K | 1.05M | 536.00K | 566.00K | 7.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 665.00K | 1.05M | 536.00K | 566.00K | 7.21M |
| Cost of Revenue | -73.15M | 26.26M | 26.88M | 24.86M | -62.87M |
| Gross Profit | 73.82M | -25.21M | -26.34M | -24.29M | 70.08M |
| SG&A Expenses | 8.02M | 7.41M | 7.77M | 7.08M | 6.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.38M | 33.67M | 34.65M | 31.94M | 28.57M |
| Operating Income | -36.71M | -32.62M | -34.11M | -31.37M | -21.36M |
| Income Before Tax | -35.81M | -29.89M | -31.66M | -30.14M | -19.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.81M | -29.89M | -31.66M | -30.14M | -19.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.81M | -29.89M | -31.66M | -30.14M | -19.61M |
| EBIT | -36.71M | -32.62M | -34.11M | -31.37M | -21.36M |
| EBITDA | -36.00M | -31.60M | -33.00M | -30.12M | -20.08M |
| EPS Basic | -0.63 | -0.56 | -0.60 | -0.63 | -0.41 |
| Normalized Basic EPS | -0.38 | -0.35 | -0.37 | -0.39 | -0.26 |
| EPS Diluted | -0.63 | -0.56 | -0.60 | -0.63 | -0.41 |
| Normalized Diluted EPS | -0.38 | -0.35 | -0.37 | -0.39 | -0.26 |
| Average Basic Shares Outstanding | 56.59M | 53.35M | 52.93M | 47.90M | 47.83M |
| Average Diluted Shares Outstanding | 56.59M | 53.35M | 52.93M | 47.90M | 47.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |